PURPOSE: The number of cases of drug abuse is increased, recently. One of the substances being abused is Dextrometorphan (DMP), it is a cough medicine, that is sold over the counter and it is cheap. The medicine can give a tripping effect if it used in relatively higher doses that it is recommended, such as slurred speech, vomitus , or physiatric disorder. Beside that, it have adverse reactions in respiratory system, and it may resulted fatal consequence. Purpose of this study is to describe the clinical pictures of dextromethorphan abuse patients which were admitted to Emergency Department of Hasan Sadikin General Hospital Bandung.
METHODS: This is descriptive study that describing the clinical profiles, x-ray feature, and lab profile in the setting of DMP intoxication in Hasan Sadikin General Hospital. The subjects are patient admitted to the hospital from March 2009 to August 2009.
RESULTS: We reported a total of 24 patients admitted to Hasan Sadikin General Hospital, all of the patient is male, at the age mean 20.6 years old. The average of DMP consumption is 36.25 tablets. Eleven patients (45.8 %) patients admitted to the hospital within the first 36 hours after the exposure, 22 patients (91.6%) took DMP and alcohol, 23 patients (92%) had respiratory distress, altered mental status, and their chest X-ray shown bilateral infiltrate that met ARDS criteria. Among them, 13 patients (54.16 %) required mechanical ventilation, and 4 patients (16%) were death due to respiratory failure. The rest of the patient recovered. Total length of stay was 5±3 days.
CONCLUSION: This study revealed a large number cases of DMP intoxication admitted to our hospital met the criteria of ARDS, most of them required mechanical ventilation. The DMP abuse above the recommended dose needs to be taken care immediately and holistic, considering to its fatal consequences.
CLINICAL IMPLICATIONS: Due to its serious clinical consequences, the health care authority must strengthen the regulation on DMP marketing.
DISCLOSURE: Arto Yuwono, No Financial Disclosure Information; No Product/Research Disclosure Information